Seattle Genetics Inc /Wa Sample Contracts

among
Securities Purchase Agreement • May 15th, 2003 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware
Sample 1Sample 2Sample 3See All (1k)
AutoNDA by SimpleDocs
UNDERWRITING AGREEMENT SEATTLE GENETICS, INC. 7,142,858 Shares of Common Stock Underwriting Agreement
Underwriting Agreement • July 24th, 2019 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York

Seattle Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 7,142,858 shares of common stock, par value $ 0.001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,071,428 shares of Common Stock of the Company solely to cover over-allotments (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.

Sample 1Sample 2Sample 3See All (930)
RECITALS:
Executive Employment Agreement • March 28th, 2003 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington
Sample 1Sample 2Sample 3See All (431)
SEAGEN INC. AND _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________
Preferred Stock Warrant Agreement • December 29th, 2020 • Seagen Inc. • Biological products, (no disgnostic substances) • New York

THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between SEAGEN INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (429)
EXHIBIT 4.2 INVESTOR RIGHTS AGREEMENT
Investor Rights Agreement • May 15th, 2003 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware
Sample 1Sample 2Sample 3See All (410)
SEATTLE GENETICS, INC. AND , As WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF
Common Stock Warrant Agreement • January 31st, 2018 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York

THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between SEATTLE GENETICS, INC., a Delaware corporation (the “Company”) and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (361)
SEAGEN INC. AND _____________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________
Warrant Agreement • December 29th, 2020 • Seagen Inc. • Biological products, (no disgnostic substances) • New York

THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between SEAGEN INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (338)
EXHIBIT 10.2 EXECUTION COPY OPTION AGREEMENT, dated as of May 12, 2003 among SEATTLE GENETICS, INC., a Delaware corporation (the "Company"), and the other parties hereto (each an "Optionee"). In order to induce the Optionees to agree to purchase from...
Option Agreement • May 15th, 2003 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware
Sample 1Sample 2Sample 3See All (259)
AGREEMENT AND PLAN OF MERGER
Merger Agreement • January 31st, 2018 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware

This Agreement and Plan of Merger (this “Agreement”), dated as of January 30, 2018, is among Seattle Genetics, Inc., a Delaware corporation (“Parent”), Valley Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), and Cascadian Therapeutics, Inc., a Delaware corporation (the “Company”). Capitalized terms not otherwise defined herein shall have the respective meanings set forth in Annex A and Exhibit A attached hereto, as applicable.

Sample 1Sample 2Sample 3See All (201)
SEAGEN INC. AND _____________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________
Warrant Agreement • December 29th, 2020 • Seagen Inc. • Biological products, (no disgnostic substances) • New York

THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between SEAGEN INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (144)
INDEMNIFICATION AGREEMENT
Indemnification Agreement • February 23rd, 2001 • Seattle Genetics Inc /Wa • Services-commercial physical & biological research • Delaware

This Indemnification Agreement (the "Agreement") is made as of December , 2000, by and between Seattle Genetics, Inc., a Delaware corporation (the "Company"), and «IndemniteeName» (the "Indemnitee").

Sample 1Sample 2Sample 3See All (88)
RECITALS The Company and the Requisite Purchasers hereby agree to an amendment to the Purchase Agreement, on the terms and subject to the conditions set forth herein. NOW, THEREFORE, in consideration of the mutual covenants and agreements contained in...
Securities Purchase Agreement • June 5th, 2003 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2Sample 3See All (58)
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • September 11th, 2015 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York

This Registration Rights Agreement (this “Agreement”) is made as of September 10, 2015, by and between Seattle Genetics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.

Sample 1Sample 2Sample 3See All (39)
SEATTLE GENETICS, INC. Common Stock UNDERWRITING AGREEMENT dated March 29, 2006
Underwriting Agreement • March 30th, 2006 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2Sample 3See All (34)
AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • October 27th, 2016 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington

THIS AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 26th day of October, 2016, by and between SEATTLE GENETICS, INC., a Delaware corporation (“Company”) and Clay B. Siegall (“Executive”).

Sample 1Sample 2Sample 3See All (14)
SEATTLE GENETICS, INC. 5,740,000 Shares of Common Stock Underwriting Agreement
Underwriting Agreement • January 28th, 2009 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York

Seattle Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the one or more several Underwriters listed in Schedule 1 hereto (whether one or more, the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 5,740,000 shares of common stock, par value $0.001 per share, of the Company (the “Shares”). The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are herein referred to as the “Stock”.

Sample 1Sample 2Sample 3See All (13)
10,000,000 Shares SEATTLE GENETICS, INC. Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENT February 2, 2011
Underwriting Agreement • February 2nd, 2011 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York

Seattle Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 10,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,500,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are herein referred to as the “Stock”.

Sample 1Sample 2Sample 3See All (11)
AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • July 31st, 2020 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington

THIS AMEDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 15th day of April, 2020, by and between SEATTLE GENETICS, INC., a Delaware corporation (“Company”) and Charles Romp (“Executive”).

Sample 1Sample 2Sample 3See All (10)
2- 1.2 Board of Directors. Executive shall become a member of the Board of Directors of the Company on the Start Date. The Board of Directors of the Company shall take whatever steps are necessary to continue to nominate Executive for election to the...
Executive Employment Agreement • February 15th, 2023 • Seagen Inc. • Biological products, (no disgnostic substances)
Sample 1Sample 2Sample 3See All (8)
EXHIBIT 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER...
Securities Purchase Agreement • May 15th, 2003 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware
Sample 1Sample 2Sample 3See All (7)
RECITALS
Clinical Supply Agreement • March 28th, 2003 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • California
Sample 1Sample 2Sample 3See All (5)
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • May 1st, 2017 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York

This Registration Rights Agreement (this “Agreement”), dated as of February 10, 2017, by and between Immunomedics, Inc., a Delaware corporation (the “Company”), and Seattle Genetics, Inc., a Delaware corporation (together with its permitted successors and assigns, the “Purchaser”).

Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Contract
Stock Option Agreement • October 28th, 2021 • Seagen Inc. • Biological products, (no disgnostic substances) • Delaware
Sample 1Sample 2Sample 3See All (4)
WARRANT AGREEMENT
Warrant Agreement • May 1st, 2017 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York

WARRANT AGREEMENT, dated as of February 16, 2017 (this “Agreement”), by and among Immunomedics, Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, Inc., a Pennsylvania corporation (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (4)
EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • March 9th, 2007 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington

THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 22nd day of May, 2006, by and between SEATTLE GENETICS, INC., a Delaware corporation (“Company”), and Pamela A. Trail (“Executive”).

Sample 1Sample 2Sample 3See All (4)
Contract
Stock Option Agreement • October 28th, 2021 • Seagen Inc. • Biological products, (no disgnostic substances)
Sample 1Sample 2Sample 3See All (4)
LICENSE AGREEMENT No. 651-O1.LIC
License Agreement • November 26th, 2010 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Arizona

THIS AGREEMENT (the “Agreement”), made this 3rd day of February, 2000 (the “EFFECTIVE DATE”), is by and between the ARIZONA BOARD OF REGENTS, a body corporate of the State of Arizona, acting on behalf of and for ARIZONA STATE UNIVERSITY, of Tempe, Arizona (“ASU”) and Seattle Genetics, Inc., a corporation organized under the laws of Delaware having its principal place of business located at 22215 26th Avenue SE, Bothell, Washington 98021 (“LICENSEE”).

Sample 1Sample 2Sample 3
Contract
Asset Purchase Agreement • April 13th, 2018 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Sample 1Sample 2Sample 3
LICENSE AGREEMENT
License Agreement • November 26th, 2010 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Florida

This License Agreement (the “Agreement”) is entered into and made effective the 20th day of September, 1999 (the “Effective Date”) between UNIVERSITY OF MIAMI and its School of Medicine, whose principal place of business is at 1600 N.W. 10th Avenue, Miami, Florida 33136 (hereinafter referred to as “LICENSOR”) and Seattle Genetics, Inc., whose principal place of business is at 22215 26th Avenue S.E., Suite 3000, Bothell, Washington 98021, hereinafter referred to as “LICENSEE”).

Sample 1Sample 2Sample 3
SEATTLE GENETICS, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT
Stock Option Agreement • October 26th, 2018 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware

THIS STOCK OPTION AGREEMENT (the "Agreement") dated %%OPTION_DATE,'MM/DD/YYYY'%-% ("Grant Date") between Seattle Genetics, Inc., a Delaware corporation (the "Company"), and %%FIRST_NAME%-% %%MIDDLE_NAME%-% %%LAST_NAME%-% ("Optionee"), is entered into as follows:

Sample 1Sample 2Sample 3
TERMINATION AGREEMENT
Termination Agreement • September 15th, 2017 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York

THIS TERMINATION AGREEMENT (this “Termination Agreement”) is made and entered into effective as of the Termination Effective Date by and between IMMUNOMEDICS, INC., a Delaware corporation (“IMMU”), and SEATTLE GENETICS, INC., a Delaware corporation (“SGEN”). Each of IMMU and SGEN may be referenced herein individually as a “Party”and collectively as the “Parties”.

Sample 1Sample 2Sample 3
STOCK PURCHASE AGREEMENT
Stock Purchase Agreement • May 1st, 2017 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York

This Stock Purchase Agreement (this “Agreement”) is dated as of February 10, 2017 (the “Effective Date”), by and between Immunomedics, Inc., a Delaware corporation (the “Company”), and Seattle Genetics, Inc., a Delaware corporation (together with any valid assignees of its rights hereunder pursuant to Section 5.6, the “Purchaser”).

Sample 1Sample 2Sample 3
AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT GENENTECH, INC. AND SEATTLE GENETICS, INC.
Development and License Agreement • March 6th, 2001 • Seattle Genetics Inc /Wa • Services-commercial physical & biological research • Washington

This Amended and Restated Development and License Agreement (the "Agreement") is made effective as of March 2, 2001 (the "Agreement") by and between Genentech, Inc. ("GNE"), a Delaware corporation with its principal office at 1 DNA Way, South San Francisco, California 94080 and Seattle Genetics, Inc. ("SG"), a Delaware corporation with its principal office at 22215 26th Avenue SE, Bothell, Washington 98021, each on behalf of itself and its Affiliates. GNE and SG are sometimes referred to herein individually as a "Party" and collectively as the "Parties," and references to "GNE" and "SG" shall include their respective Affiliates.

Sample 1Sample 2Sample 3
7,000,000 Shares Seattle Genetics, Inc. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • February 5th, 2004 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York

Seattle Genetics, Inc., a Delaware corporation (the “Company”) proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of 7,000,000 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 1,050,000 shares (the “Option Shares”) of Common Stock from the Company. The Firm Shares and the Option Shares are collectively called the “Shares.”

Sample 1Sample 2Sample 3
LICENSE AGREEMENT BETWEEN BRISTOL-MYERS SQUIBB AND COMPANY SEATTLE GENETICS, INC. DATED AS OF MARCH 30, 1998
License Agreement • February 23rd, 2001 • Seattle Genetics Inc /Wa • Services-commercial physical & biological research • New York

THIS LICENSE AGREEMENT (this "Agreement") dated as of March 30, 1998 by and between Bristol-Myers Squibb Company, a corporation duly organized and existing under the laws of the State of Delaware, having offices at P.O. Box 4000, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, for and on behalf of itself and its Affiliates ("BMS"), and Seattle Genetics, Inc., a corporation duly organized and existing under the laws of the State of Delaware, having offices at 22215 26th Avenue, SE, Bothell, Washington 98021 ("SGI").

Sample 1Sample 2
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!